THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING1 IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the impr ...

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials. WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®. ABBV-303, an investigational drug being developed fo ...

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building shareholder value. In fact, to become a dividend king a company must increase their dividend for at least 50 consecutive years.  You won’t find these companies on any “Magnificent 7” list of tech stocks. They aren’t going to be leading the AI revolution or renewable energy transformation. However, what dividend ...

The latest trading session saw AbbVie (ABBV) ending at $178.91, denoting a +1.62% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.8%. Elsewhere, the Dow saw an upswing of 0.23%, while the tech-heavy Nasdaq appreciated by 1.14%.The drugmaker's stock has climbed by 5.05% in the past month, exceeding the Medical sector's gain of 3.58% and lagging the S&P 500's gain of 5.2%.Market participants will be closely following the financial results of AbbVie in i ...

It’s often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks.  However, that virtue can be sorely lacking among investors. In good times, investors are frequently drawn to the next shiny object. And when growth is hard to come by, they can move into more speculative assets, seeking growth at all costs. But history says investors with a long-term focus can still do better looking at solid blue-chip stocks. These stocks frequently are in defens ...

Since the beginning of the 20th century, dividend stocks have accounted for 75% of the total returns in the U.S. stock market. Dividend growth stocks, which are companies that regularly increase their cash payouts to shareholders annually, have significantly outperformed the majority of other asset classes over this 124-year span.The primary reason for this is the power of compounding. By owning a dividend growth stock and reinvesting the dividends each quarter, your investment can experience exponential gr ...

-   Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation -   OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, toda ...

-   A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong and durable treatment responses -   In November 2023, the FDA granted this investigational indication a Breakthrough Therapy Designation (BTD) NORTH CHICAGO, Ill., Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The FDA grants Priority Review to investigational ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity. Apurva Saraf, President and CEO of Cosette Pharma, stated, "This is a pivotal product appr ...